WO2003082229A1 - Composite powder and cosmetic containing the same - Google Patents
Composite powder and cosmetic containing the same Download PDFInfo
- Publication number
- WO2003082229A1 WO2003082229A1 PCT/JP2003/003946 JP0303946W WO03082229A1 WO 2003082229 A1 WO2003082229 A1 WO 2003082229A1 JP 0303946 W JP0303946 W JP 0303946W WO 03082229 A1 WO03082229 A1 WO 03082229A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composite powder
- powder
- zinc
- zinc oxide
- antibacterial
- Prior art date
Links
- 239000000843 powder Substances 0.000 title claims abstract description 279
- 239000002131 composite material Substances 0.000 title claims abstract description 154
- 239000002537 cosmetic Substances 0.000 title claims abstract description 45
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 198
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 106
- 239000011787 zinc oxide Substances 0.000 claims abstract description 99
- -1 alkali metal salt Chemical class 0.000 claims abstract description 74
- 238000001179 sorption measurement Methods 0.000 claims abstract description 51
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 50
- UOURRHZRLGCVDA-UHFFFAOYSA-D pentazinc;dicarbonate;hexahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Zn+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2].[O-]C([O-])=O.[O-]C([O-])=O UOURRHZRLGCVDA-UHFFFAOYSA-D 0.000 claims abstract description 49
- 230000000694 effects Effects 0.000 claims abstract description 47
- 239000002585 base Substances 0.000 claims abstract description 32
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 30
- 230000009471 action Effects 0.000 claims abstract description 29
- 102000004190 Enzymes Human genes 0.000 claims abstract description 20
- 108090000790 Enzymes Proteins 0.000 claims abstract description 20
- 230000037307 sensitive skin Effects 0.000 claims abstract description 7
- 230000003213 activating effect Effects 0.000 claims abstract description 3
- 238000012360 testing method Methods 0.000 claims description 155
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 68
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 68
- 229940127126 plasminogen activator Drugs 0.000 claims description 68
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 39
- 239000007864 aqueous solution Substances 0.000 claims description 34
- 238000006243 chemical reaction Methods 0.000 claims description 26
- 239000003242 anti bacterial agent Substances 0.000 claims description 25
- 230000005764 inhibitory process Effects 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 23
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 22
- 239000000377 silicon dioxide Substances 0.000 claims description 19
- 239000006185 dispersion Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 14
- 229910052751 metal Inorganic materials 0.000 claims description 13
- 239000002184 metal Substances 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 12
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 11
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 11
- 239000004246 zinc acetate Substances 0.000 claims description 11
- 235000013904 zinc acetate Nutrition 0.000 claims description 11
- 239000011592 zinc chloride Substances 0.000 claims description 11
- 235000005074 zinc chloride Nutrition 0.000 claims description 11
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 11
- 229960001763 zinc sulfate Drugs 0.000 claims description 11
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 206010000496 acne Diseases 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 8
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 8
- 230000002194 synthesizing effect Effects 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical class [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 6
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 6
- 206010013786 Dry skin Diseases 0.000 claims description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 5
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 5
- 229910052744 lithium Inorganic materials 0.000 claims description 5
- 229920002050 silicone resin Polymers 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- 239000004952 Polyamide Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 229920002647 polyamide Polymers 0.000 claims description 4
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 abstract description 9
- 208000017520 skin disease Diseases 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 65
- 230000000843 anti-fungal effect Effects 0.000 description 61
- 239000000203 mixture Substances 0.000 description 52
- 239000000454 talc Substances 0.000 description 39
- 229910052623 talc Inorganic materials 0.000 description 39
- 238000009472 formulation Methods 0.000 description 34
- 229940121375 antifungal agent Drugs 0.000 description 31
- 229910000029 sodium carbonate Inorganic materials 0.000 description 29
- 210000003491 skin Anatomy 0.000 description 26
- 238000003756 stirring Methods 0.000 description 22
- 239000000047 product Substances 0.000 description 20
- 229920001296 polysiloxane Polymers 0.000 description 19
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 18
- 229910052725 zinc Inorganic materials 0.000 description 18
- 239000011701 zinc Substances 0.000 description 18
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 17
- 238000002156 mixing Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 239000012071 phase Substances 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 239000003205 fragrance Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 239000000417 fungicide Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 8
- 239000004698 Polyethylene Substances 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 230000007794 irritation Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229920000573 polyethylene Polymers 0.000 description 7
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 7
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 6
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 6
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 description 6
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 230000001771 impaired effect Effects 0.000 description 6
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 6
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 5
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 5
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 5
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 5
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 5
- 238000010304 firing Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000009036 growth inhibition Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
- 239000003429 antifungal agent Substances 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 4
- 210000001339 epidermal cell Anatomy 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000010419 fine particle Substances 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000010445 mica Substances 0.000 description 4
- 229910052618 mica group Inorganic materials 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 229940012957 plasmin Drugs 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 3
- 235000002233 Penicillium roqueforti Nutrition 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 150000002736 metal compounds Chemical class 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 229960001679 octinoxate Drugs 0.000 description 3
- 239000012860 organic pigment Substances 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- 239000010457 zeolite Substances 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101710097382 Fibrinolytic protease Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 229910021536 Zeolite Inorganic materials 0.000 description 2
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 239000004566 building material Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229910000420 cerium oxide Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000012969 defense response to bacterium Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000001023 inorganic pigment Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000007788 roughening Methods 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000019983 sodium metaphosphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000002966 varnish Substances 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- GYDYJUYZBRGMCC-INIZCTEOSA-N (2s)-2-amino-6-(dodecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCC(=O)NCCCC[C@H](N)C(O)=O GYDYJUYZBRGMCC-INIZCTEOSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- SUQPHYAFSSXBNB-UHFFFAOYSA-N 16-methylheptadecyl dihydrogen phosphate Chemical compound CC(C)CCCCCCCCCCCCCCCOP(O)(O)=O SUQPHYAFSSXBNB-UHFFFAOYSA-N 0.000 description 1
- CDNNKGWZSNSADW-UHFFFAOYSA-N 2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16,18,18,20,20-icosamethyl-1,3,5,7,9,11,13,15,17,19-decaoxa-2,4,6,8,10,12,14,16,18,20-decasilacycloicosane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 CDNNKGWZSNSADW-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- QEZGRWSAUJTDEZ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(piperidine-1-carbonyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)C(=O)N1CCCCC1 QEZGRWSAUJTDEZ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000995051 Brenda Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000005747 Chlorothalonil Substances 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000191070 Escherichia coli ATCC 8739 Species 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000692885 Nymphalis antiopa Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000797947 Paria Species 0.000 description 1
- 241000228168 Penicillium sp. Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241001103617 Pseudomonas aeruginosa ATCC 15442 Species 0.000 description 1
- 241000220156 Saxifraga Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- RJDOZRNNYVAULJ-UHFFFAOYSA-L [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[F-].[F-].[Mg++].[Mg++].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[K+] Chemical compound [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[F-].[F-].[Mg++].[Mg++].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[K+] RJDOZRNNYVAULJ-UHFFFAOYSA-L 0.000 description 1
- KDHWZXMNULXDFH-UHFFFAOYSA-N [Zn].[Zr] Chemical compound [Zn].[Zr] KDHWZXMNULXDFH-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- DBJUEJCZPKMDPA-UHFFFAOYSA-N acetic acid;zinc Chemical group [Zn].CC(O)=O DBJUEJCZPKMDPA-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229910052898 antigorite Inorganic materials 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- HGKOWIQVWAQWDS-UHFFFAOYSA-N bis(16-methylheptadecyl) 2-hydroxybutanedioate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)C(=O)OCCCCCCCCCCCCCCCC(C)C HGKOWIQVWAQWDS-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- HFNQLYDPNAZRCH-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O.OC(O)=O HFNQLYDPNAZRCH-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 239000003922 charged colloid Substances 0.000 description 1
- JBTHDAVBDKKSRW-UHFFFAOYSA-N chembl1552233 Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 JBTHDAVBDKKSRW-UHFFFAOYSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- CRQQGFGUEAVUIL-UHFFFAOYSA-N chlorothalonil Chemical compound ClC1=C(Cl)C(C#N)=C(Cl)C(C#N)=C1Cl CRQQGFGUEAVUIL-UHFFFAOYSA-N 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- VQWFNAGFNGABOH-UHFFFAOYSA-K chromium(iii) hydroxide Chemical compound [OH-].[OH-].[OH-].[Cr+3] VQWFNAGFNGABOH-UHFFFAOYSA-K 0.000 description 1
- 229910052620 chrysotile Inorganic materials 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 229910000428 cobalt oxide Inorganic materials 0.000 description 1
- IVMYJDGYRUAWML-UHFFFAOYSA-N cobalt(ii) oxide Chemical compound [Co]=O IVMYJDGYRUAWML-UHFFFAOYSA-N 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- YGANSGVIUGARFR-UHFFFAOYSA-N dipotassium dioxosilane oxo(oxoalumanyloxy)alumane oxygen(2-) Chemical compound [O--].[K+].[K+].O=[Si]=O.O=[Al]O[Al]=O YGANSGVIUGARFR-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- VPWFPZBFBFHIIL-UHFFFAOYSA-L disodium 4-[(4-methyl-2-sulfophenyl)diazenyl]-3-oxidonaphthalene-2-carboxylate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 VPWFPZBFBFHIIL-UHFFFAOYSA-L 0.000 description 1
- OOYIOIOOWUGAHD-UHFFFAOYSA-L disodium;2',4',5',7'-tetrabromo-4,5,6,7-tetrachloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(Br)=C([O-])C(Br)=C1OC1=C(Br)C([O-])=C(Br)C=C21 OOYIOIOOWUGAHD-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002338 electrophoretic light scattering Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000002979 fabric softener Substances 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009408 flooring Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000012770 industrial material Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910001947 lithium oxide Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000012243 magnesium silicates Nutrition 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229940041290 mannose Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229910052627 muscovite Inorganic materials 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910000273 nontronite Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000001699 photocatalysis Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 229940098458 powder spray Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 229910052903 pyrophyllite Inorganic materials 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- 229960004546 thiabendazole Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- CWBIFDGMOSWLRQ-UHFFFAOYSA-N trimagnesium;hydroxy(trioxido)silane;hydrate Chemical compound O.[Mg+2].[Mg+2].[Mg+2].O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-] CWBIFDGMOSWLRQ-UHFFFAOYSA-N 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 238000004876 x-ray fluorescence Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
- SRWMQSFFRFWREA-UHFFFAOYSA-M zinc formate Chemical compound [Zn+2].[O-]C=O SRWMQSFFRFWREA-UHFFFAOYSA-M 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 1
- 229910000165 zinc phosphate Inorganic materials 0.000 description 1
- XDWXRAYGALQIFG-UHFFFAOYSA-L zinc;propanoate Chemical compound [Zn+2].CCC([O-])=O.CCC([O-])=O XDWXRAYGALQIFG-UHFFFAOYSA-L 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09C—TREATMENT OF INORGANIC MATERIALS, OTHER THAN FIBROUS FILLERS, TO ENHANCE THEIR PIGMENTING OR FILLING PROPERTIES ; PREPARATION OF CARBON BLACK ; PREPARATION OF INORGANIC MATERIALS WHICH ARE NO SINGLE CHEMICAL COMPOUNDS AND WHICH ARE MAINLY USED AS PIGMENTS OR FILLERS
- C09C1/00—Treatment of specific inorganic materials other than fibrous fillers; Preparation of carbon black
- C09C1/0015—Pigments exhibiting interference colours, e.g. transparent platelets of appropriate thinness or flaky substrates, e.g. mica, bearing appropriate thin transparent coatings
- C09C1/0021—Pigments exhibiting interference colours, e.g. transparent platelets of appropriate thinness or flaky substrates, e.g. mica, bearing appropriate thin transparent coatings comprising a core coated with only one layer having a high or low refractive index
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09C—TREATMENT OF INORGANIC MATERIALS, OTHER THAN FIBROUS FILLERS, TO ENHANCE THEIR PIGMENTING OR FILLING PROPERTIES ; PREPARATION OF CARBON BLACK ; PREPARATION OF INORGANIC MATERIALS WHICH ARE NO SINGLE CHEMICAL COMPOUNDS AND WHICH ARE MAINLY USED AS PIGMENTS OR FILLERS
- C09C1/00—Treatment of specific inorganic materials other than fibrous fillers; Preparation of carbon black
- C09C1/02—Compounds of alkaline earth metals or magnesium
- C09C1/021—Calcium carbonates
- C09C1/022—Treatment with inorganic compounds
- C09C1/024—Coating
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09C—TREATMENT OF INORGANIC MATERIALS, OTHER THAN FIBROUS FILLERS, TO ENHANCE THEIR PIGMENTING OR FILLING PROPERTIES ; PREPARATION OF CARBON BLACK ; PREPARATION OF INORGANIC MATERIALS WHICH ARE NO SINGLE CHEMICAL COMPOUNDS AND WHICH ARE MAINLY USED AS PIGMENTS OR FILLERS
- C09C1/00—Treatment of specific inorganic materials other than fibrous fillers; Preparation of carbon black
- C09C1/28—Compounds of silicon
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09C—TREATMENT OF INORGANIC MATERIALS, OTHER THAN FIBROUS FILLERS, TO ENHANCE THEIR PIGMENTING OR FILLING PROPERTIES ; PREPARATION OF CARBON BLACK ; PREPARATION OF INORGANIC MATERIALS WHICH ARE NO SINGLE CHEMICAL COMPOUNDS AND WHICH ARE MAINLY USED AS PIGMENTS OR FILLERS
- C09C1/00—Treatment of specific inorganic materials other than fibrous fillers; Preparation of carbon black
- C09C1/28—Compounds of silicon
- C09C1/30—Silicic acid
- C09C1/3045—Treatment with inorganic compounds
- C09C1/3054—Coating
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09C—TREATMENT OF INORGANIC MATERIALS, OTHER THAN FIBROUS FILLERS, TO ENHANCE THEIR PIGMENTING OR FILLING PROPERTIES ; PREPARATION OF CARBON BLACK ; PREPARATION OF INORGANIC MATERIALS WHICH ARE NO SINGLE CHEMICAL COMPOUNDS AND WHICH ARE MAINLY USED AS PIGMENTS OR FILLERS
- C09C1/00—Treatment of specific inorganic materials other than fibrous fillers; Preparation of carbon black
- C09C1/40—Compounds of aluminium
- C09C1/407—Aluminium oxides or hydroxides
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09C—TREATMENT OF INORGANIC MATERIALS, OTHER THAN FIBROUS FILLERS, TO ENHANCE THEIR PIGMENTING OR FILLING PROPERTIES ; PREPARATION OF CARBON BLACK ; PREPARATION OF INORGANIC MATERIALS WHICH ARE NO SINGLE CHEMICAL COMPOUNDS AND WHICH ARE MAINLY USED AS PIGMENTS OR FILLERS
- C09C1/00—Treatment of specific inorganic materials other than fibrous fillers; Preparation of carbon black
- C09C1/40—Compounds of aluminium
- C09C1/42—Clays
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09C—TREATMENT OF INORGANIC MATERIALS, OTHER THAN FIBROUS FILLERS, TO ENHANCE THEIR PIGMENTING OR FILLING PROPERTIES ; PREPARATION OF CARBON BLACK ; PREPARATION OF INORGANIC MATERIALS WHICH ARE NO SINGLE CHEMICAL COMPOUNDS AND WHICH ARE MAINLY USED AS PIGMENTS OR FILLERS
- C09C3/00—Treatment in general of inorganic materials, other than fibrous fillers, to enhance their pigmenting or filling properties
- C09C3/06—Treatment with inorganic compounds
- C09C3/063—Coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/12—Face or body powders for grooming, adorning or absorbing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/14—Preparations for removing make-up
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/80—Particles consisting of a mixture of two or more inorganic phases
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09C—TREATMENT OF INORGANIC MATERIALS, OTHER THAN FIBROUS FILLERS, TO ENHANCE THEIR PIGMENTING OR FILLING PROPERTIES ; PREPARATION OF CARBON BLACK ; PREPARATION OF INORGANIC MATERIALS WHICH ARE NO SINGLE CHEMICAL COMPOUNDS AND WHICH ARE MAINLY USED AS PIGMENTS OR FILLERS
- C09C2200/00—Compositional and structural details of pigments exhibiting interference colours
- C09C2200/10—Interference pigments characterized by the core material
- C09C2200/102—Interference pigments characterized by the core material the core consisting of glass or silicate material like mica or clays, e.g. kaolin
Definitions
- the present invention relates to a composite powder and a cosmetic containing the same, particularly to an improvement of its antibacterial and antifungal properties, and further to a composite powder having both plasminogen activator (PA) inhibitory action and antibacterial and antifungal properties.
- PA plasminogen activator
- antibacterial and fungicide agents are used in a wide range of fields related to human clothing, food and shelter, and these are roughly classified into organic and inorganic.
- organic antibacterial and antifungal agents include paraben, triclosan, quaternary ammonium salt, chlorhexidine hydrochloride, thiabendazole, carbendazine, capyatan, fluoroforpet, and chlorothalonil.
- Inorganic antibacterial and antifungal agents are mainly silicates, phosphates, zeolites, synthetic minerals, etc., which have substituted or carried antibacterial metals such as silver, copper, and zinc.
- Substituted zeolite—silver-supported apatite, silver-supported silica gel, and the like have been put into practical use. These antibacterial antibacterial agents can be used in building materials and household goods to prevent contamination and deterioration of each product by bacteria, but they are rarely irritating to the human body. In some cases.
- organic antibacterial and fungicides such as paraben, which are generally used as preservatives for cosmetics, may cause skin irritation, development of an excellent inorganic antibacterial and antifungal agent has been desired.
- An object of the present invention is to provide a composite powder having excellent antibacterial and antifungal properties and further having a plasminogen activator-inhibiting action, and a cosmetic containing the same, in view of the above conventional problems.
- the first subject of the present invention is that:
- Zinc oxide and / or basic zinc carbonate Zinc oxide and / or basic zinc carbonate
- the site where zinc oxide or Z or basic zinc carbonate is complexed with the alkali metal salt is an action site having the inhibitory or activating properties of the enzyme.
- the zinc oxide and / or the basic zinc carbonate and the alkali metal salt are included, embedded, or included in the base powder.
- the action site and the adsorption site are formed in stripes or spots with respect to the inert powder.
- the alkali metal salt is included, embedded, or included in zinc oxide and Z or basic zinc carbonate.
- the specific enzyme is preferably a plasminogen activator
- the action site is preferably a site having a plasminogen activator inhibitory property.
- the alkali metal salt is preferably at least one selected from the group consisting of lithium, sodium, and potassium hydroxides, hydrogen carbonates, and carbonates.
- the ⁇ potential of the adsorption site at a pH used is a negative value, and the ⁇ potential of the adsorption site at ⁇ 7.5 is 11 OmV or less.
- the adsorption site is one or more selected from the group consisting of silica, talc, myriki, polyamide, polyethylene methacrylate, and silicone resin.
- the content of the alkali metal salt is 0.5 to 50% by mass based on the whole powder, and the content of zinc oxide and zinc oxide or basic zinc carbonate is based on the whole powder. It is preferably 5 to 75% by mass.
- the composite powder it is preferable to use zinc acetate or zinc chloride or zinc sulfate containing acetic acid at the same time as a raw material for synthesizing zinc oxide and Z or basic zinc carbonate.
- the composite powder preferably has a plasminogen activator inhibition rate of 40% or more.
- the plasminogen activator (PA) inhibition rate is measured by the following method.
- 1 ⁇ of the 10% by mass aqueous dispersion is 9 to 14.
- the amounts of the two aqueous solutions that is, an aqueous solution containing zinc ion and an aqueous solution, are adjusted so that the pH of the reaction solution is kept constant at 7 to 10 at normal temperature and normal pressure.
- the product is continuously supplied to a reaction vessel containing the base powder, and the product is obtained by filtration, washing with water, and drying.
- a second subject of the present invention is a cosmetic comprising the above-mentioned composite powder. It is preferable that the cosmetic does not substantially contain another antibacterial and protective agent.
- the composite powder can also be used as a skin roughness improving agent, a sensitive skin care agent, and an acne skin care agent.
- FIG. 1 is a diagram showing an example of the structure of the composite powder according to the present invention.
- FIG. 2 is a diagram showing another example of the structure of the composite powder according to the present invention.
- FIG. 3 is a diagram showing another example of the structure of the composite powder according to the present invention.
- FIG. 4 is a diagram showing an example of a method for producing a composite powder according to the present invention.
- FIG. 5 is a diagram showing a method for evaluating the antibacterial and antimicrobial performance of the composite powder according to the present invention.
- FIG. 6 is a diagram showing the relationship between the composite powder aqueous dispersion pH according to the present invention and the performance of a defense force against blue power.
- the composite powder according to the present invention is a composite of a base powder, zinc oxide and Z or basic zinc carbonate, and an alkali metal salt.
- the base powder surface is coated with zinc oxide and Z or basic zinc carbonate and an alkali metal salt in stripes or spots;
- zinc oxide and Z or basic zinc carbonate and an alkali metal salt are preferably encapsulated, embedded, or encapsulated in the base powder, but a condition in which the effects of the present invention are not impaired is preferable. It is not limited to this. Further, it is preferable that the alkali metal salt is included, embedded, or included in zinc oxide and zinc oxide or basic zinc carbonate. Zinc and Z or basic zinc carbonate
- the method for synthesizing zinc oxide and z or basic zinc carbonate in the composite powder according to the present invention is roughly classified into a wet method in which the powder is synthesized in an aqueous solution, and a dry method in which no solution is directly interposed.
- a basic zinc carbonate can be obtained by mixing an aqueous solution containing zinc ions and an aqueous solution containing carbonate ions, and washing, filtering, and drying the product. Furthermore, when this is calcined, zinc oxide can be obtained.
- dry methods include heating zinc metal in air (French method) and zinc ore.
- the composite powder according to the present invention contains an alkali metal salt. Specifically, it is preferable to contain one or more alkali metal salts selected from hydroxides of lithium, sodium, and potassium, hydrogen carbonates, and carbonates.
- the alkali metal salt is particularly preferably sodium carbonate or potassium carbonate.
- the alkali metal salt may include one or more of the above.
- zinc oxide and Z or basic zinc carbonate are fine particles, they may be used in cosmetics. In this case, the compounding amount is large, and the spread becomes heavy. However, this drawback is eliminated by compounding with the base powder for ease of use.
- Examples of the base powder include the following.
- Power Olinites such as power oli- nite, deckite, naklite, haloid site, antigorite, chrysotile, smectites such as pyrophyllite, montmorillonite, nontronite, savonite, hectorite, bentonite, and sericite.
- Irites such as muscovite, mica, lithia mica, and synthetic mica; silicates such as hyderite and aluminum magnesium silicate; calcium compounds such as tricalcium phosphate and hydroxypatite; and magnesium silicates such as talc and jammonite.
- Single-component powders such as family, silica, alumina, etc., other zeolites, silicone powder, glass powder, glass beads, titanium oxide-containing silica, zinc oxide-containing silica, iron oxide-containing silica, cerium oxide-containing silica, oxide Hard capsules such as tan-encapsulated PMMA (polymethyl methacrylate), zinc oxide-enclosed PMMA, cerium oxide-enclosed PMMA, etc. And pearl pigments such as bismuth-one-strength.
- nylon powder examples include nylon powder, polyethylene powder, Teflon TM powder, polypropylene powder, silk powder, butyl acetate powder, polymethacrylate ester powder, polyacryl nitrinole powder, polystyrene powder, and cellulose powder.
- the base powder is an adsorption site for adsorbing a specific enzyme, and a site in which zinc oxide and Z or basic zinc carbonate and an alkali metal salt are complexed inhibits or inhibits the activity of the enzyme.
- proteolytic enzymes in epidermal cells are thought to play an important role. It has been revealed that changes in the activity of fibrinolytic proteases such as genactivators are deeply involved. Plasmin is a protease whose precursor, plasminogen, is activated by PA and plays an important role in suppressing blood clot formation in the blood coagulation system.
- Proteolytic action destroys tissues and cells, or produces harmful peptides that can cause inflammation and anaphylactic shock, such as dilation of capillaries, increased vascular permeability, contraction of smooth muscle, and pain, leading to the body Are known to have adverse effects. It has also been reported that perokinase (UK), one of the PAs, has an effect of enhancing cell proliferation.
- UK perokinase
- Skin diseases in which changes in the activity of these fibrinolytic proteases are recognized include, for example, psoriasis and pemphigus vulgaris, which are representatives of inflammatory dyskeratosis.
- psoriasis strong PA activity was observed in the parakeratotic site of the affected epidermis (Hibino et al .: Blood and vessels; 17 (6), 1986).
- pemphigus vulgaris a large amount of PA was produced in epidermal cells. Is known to convert extracellular plasminogen into plasmin, and this plasmin digests intercellular binding substances, causing tissue fluid to accumulate between cells and form intraepidermal blisters (Morio ka). S .: J. Invest.
- the adsorption site 12 is coated with the operation site 14 in a striped or spotted manner.
- the adsorption site 12 is covered with the action site 14 in a striped or spotted manner.
- the adsorption site 12 is formed in a net shape on the entire surface of the action site 14.
- the composite powder 10 formed on the base powder 16 based on the action site 14 and the adsorption site 12, Composite powder 10 carrying the action site 14 on the substrate (Fig. 2 (B)) (or composite powder 10 carrying the adsorption site 12 between the layers of the action site 14 (Fig. 2 (C))).
- the composite powder 10 in which the action site 14 is included in the adsorption site 12 (FIG. 3 (A)) (or the composite powder 10 in which the adsorption site 12 is included in the action site 14 ( FIG. 3 (B)) and the like are not particularly limited as long as the effects of the present invention are not impaired.
- Adsorption site it is preferable to adjust the coating amount, the covering ratio, and the like of the composite powder so that the function and effect at the action site can be sufficiently exhibited and the adsorption effect at the adsorption site is not hindered.
- the adsorption site is determined in relation to the enzyme to be adsorbed, but is preferably evaluated in correlation with the zeta potential of the target enzyme.
- the ⁇ potential is suitably used for evaluating the surface charge state of an object, and the ability to electrically adsorb an enzyme can be evaluated.
- the potential determine the velocity (V) of the colloid particles and the electrophoretic mobility (U) by electrophoresis.
- V L / t (L: travel distance t: time)
- U V_E.
- the target enzyme is a plasminogen activator having a positive ⁇ potential
- the ⁇ potential of the substance constituting the adsorption site preferably shows a negative value in ⁇ on the skin.
- the ⁇ potential of the substance constituting the adsorption site preferably shows a value of _10 mV or less at ⁇ 7.5, more preferably _15 mV or less, and most preferably 12 OmV or less.
- the ⁇ potential measurement method is as follows.
- the sample was dispersed in Tris-HC1 buffer with ⁇ 7.5, and the sample was subjected to ultrasonic treatment and used for measurement.
- ⁇ Potential is measured using an electrophoretic light scattering photometer L ⁇ ⁇ 600-600 manufactured by Otsuka Electronics Co., Ltd. The measurement was performed three times, and the result was expressed as the average value.
- Talc Talc (Talc JA-68R TM )-19.3 78
- Polyamide (Nai SP500 TM ) -32. 0 34
- Silicone resin (Tosharu 145A TM ) -14. 0 30
- Senorerosu (cell opening flow C one 25 TM) -. 2 0 2
- the method for measuring the U K adsorption rate is as follows.
- Tris-HC1 buffer pH 7.5
- sample suspension water 20 ⁇ L of sample suspension water
- 20 ⁇ L of 10 ⁇ g Zml precursor type UK is added here.
- filter the sample powder and collect the filtrate.
- the powder was sufficiently washed with a fixed amount of Tris-HC1 buffer, the filtrate and the washing solution were combined, and this was used as an unadsorbed UK solution.
- TintEliz a uPA biopool
- examples of the substance suitable for the adsorption site include silica, mica, and talc as the inorganic powder, and polyamide, polymethyl methacrylate, and silicone resin as the organic powder.
- the adsorption site can be composed of one or more substances. Action site
- the action site is also determined in relation to the enzyme to be acted on.
- the target enzyme is a plasminogen activator
- Metal compounds that elute zinc ions include oxides, hydroxides, nitrates, chlorides, hydrates, carbonates, bicarbonates, sulfates, borates, persulfates, and the like.
- Compounds such as forms (complexes) containing inorganic compounds contained in glycerol; glycerol phosphate, acetate, hydroxide, and ⁇ -hydroxy acid (taenate, tartrate, lactate, malic acid) Salt) or fruit acid salt, amino acid salt (aspartate, alginate, glycolate, fumarate) or fatty acid salt (palmitate, oleate, strength)
- Organic salts such as zeinates and behenylates
- particularly preferred metal compounds include zinc oxide and / or basic oxides. And zinc carbonate.
- the method for measuring the UK activity inhibition rate is as follows.
- the above-mentioned zinc oxide and / or basic zinc carbonate is mainly used, and as a mixture, one or more selected from lithium, sodium, and potassium hydroxides, hydrogencarbonates, and carbonates are used. It is preferable to contain two or more metal salts.
- the alkali metal salt is particularly preferably sodium carbonate or potassium carbonate.
- Inert powder As described above, the composite powder of the present invention may have a structure in which an adsorption site and an action site are formed on an inert powder (FIG. 2 (A)).
- the inert powder is not particularly limited as long as the effect of the present invention is not impaired, and inorganic powder, organic powder, inorganic pigment powder, organic pigment powder, or the like may be used. it can.
- PA is localized in the stratum corneum and dermis.
- various skin diseases accompanied by rough skin and abnormal keratinization activate PA, disrupt the appropriate localization of PA in the skin, and cause diffusion of PA.
- a substance having a negative ⁇ potential has an excellent ability to electrically adsorb ⁇ ⁇ .
- a composite powder having an adsorption site with a negative ⁇ potential is applied to the skin, a large amount of ⁇ generated in the skin cells is attracted to the adsorption site and localized in the upper layer of the epidermis. That is, PA is adsorbed to the adsorption site of the composite powder, and the diffusion is suppressed.
- the activation of the PA adsorbed at the adsorption site of the composite powder is suppressed by the PA inhibitory effect of the action site.
- trypsin which is classified into the same serine protease as PA, was also examined, and almost no trypsin activity was lost. That is, the action site according to the present invention does not non-specifically inhibit enzyme activity.
- PA perokinase
- tissue-type PA the former being found in healthy epidermis and the latter mainly in pathological epidermis.
- the composite powder according to the present invention is represented by those having an inhibitory action on both of these PAs.
- the PA inhibition rate is preferably at least 40%, particularly preferably at least 50%.
- the composite powder according to the present invention is characterized in that, compared to zinc oxyacid, which is an inorganic antibacterial agent that is currently generally used, zinc oxide and / or basic zinc carbonate mixed with an alkali metal salt.
- Figure 4 shows an example of the manufacturing method.
- the number of times of water washing in the water washing step is reduced by using a base powder dispersion in addition to an aqueous solution containing zinc ion and an aqueous alkali solution.
- a base powder dispersion in addition to an aqueous solution containing zinc ion and an aqueous alkali solution.
- an aqueous solution containing zinc ions, an aqueous alkaline solution, and a base powder dispersion are prepared.
- talc is used by dispersing it in ion-exchanged water as a base powder dispersion (C).
- an aqueous zinc acetate solution is used as the aqueous solution containing zinc ions (A)
- an aqueous sodium carbonate solution is used as the alkaline aqueous solution (B).
- the aqueous solution containing zinc ions (A) and the aqueous alkali solution (B) were adjusted at room temperature and normal pressure so that the pH of the reaction solution was constant at 7 to 10, while the base powder dispersion (C) ), And mix and stir.
- the product obtained in this manner can be obtained by filtering off with a centrifugal separator, washing with water, drying and further baking. In the manufacturing example shown in the figure, drying was performed at 105 ° C. for 12 hours in the drying step, and firing was performed at 300 ° C. in the firing step. Further, in order to adjust the particle diameter of the powder, a pulverization treatment or the like may be performed after firing.
- the pH during the synthesis of the composite powder is 7 to 10. If the pH during synthesis is less than 7 or more than 10, antibacterial and antifungal properties may not be exhibited.
- Raw materials for the aqueous solution containing zinc ions include inorganic salts such as zinc sulfate, zinc nitrate, zinc phosphate, zinc halide, zinc formate, zinc acetate, zinc propionate, zinc lactate, and zinc sulfate.
- Organic acid salts such as zinc sulfate and zinc citrate can be used.
- the present invention it is particularly preferable to use zinc acetate, zinc sulfate, and zinc chloride. Further, when zinc sulfate and zinc salt are used, it is preferable to add acetic acid twice as much as the mole number of zinc contained in the material. When these synthetic raw materials are used, the antibacterial and antifungal effect is particularly excellent.
- lithium, sodium, potassium hydroxide, hydrogen carbonate, carbonate and the like can be used as a raw material of the alkaline aqueous solution.
- the method for producing a composite powder according to the present invention is not limited to the above-described method, but may be applied to any other method that does not impair the effects of the present invention.
- a strong alkaline aqueous solution such as sodium hydroxide and a hydroxide power, synthesize zinc oxide directly without passing through basic zinc carbonate, and wash and filter it.
- composite powder can be obtained by drying.
- a sufficient washing is performed in the washing step of the above-mentioned method to synthesize a preliminary powder (composite aggregate of zinc oxide and the base powder) containing almost no impurities other than the base powder and the zinc oxide.
- a preliminary powder composite aggregate of zinc oxide and the base powder
- the content of zinc oxide and / or basic zinc carbonate is preferably 5 to 75% by mass of the entire composite powder. If the amount is less than 5% by mass, the desired effect may not be obtained. On the other hand, if the amount exceeds 75% by mass, the spreadability is heavy and the usability when combined with cosmetics or the like may be impaired.
- the content of the alkali metal salt is preferably 0.5 to 50% by mass of the entire composite powder. If the amount is less than 0.5% by mass, a desired antibacterial and antifungal effect may not be obtained, which is not preferable. If the content exceeds 50% by mass, the initial antibacterial performance is good, but the performance of the composition may be deteriorated due to the high hygroscopicity and dissolution of the alkali metal salt, or the antibacterial agent itself may become strongly alkaline. Therefore, it is not preferable.
- the composite powder according to the present invention has an excellent antibacterial and antifungal effect as compared with zinc oxide, which is an inorganic antibacterial agent generally used at present, due to the presence of the alkali metal salt. can get.
- zinc oxide and / or basic zinc carbonate and the alkali metal salt are sufficiently mixed, and the alkali metal salt is included in the fine aggregate of zinc oxide and / or basic zinc carbonate, the powder is simply in a powder state. Unlike the mixture of the two, the antibacterial and antifungal performance can be maintained for a long time.
- the pH of the 10% by mass aqueous dispersion of the synthesized composite powder is preferably from 9 to 14, particularly preferably from 9.5 to 12.
- the cosmetic according to the present invention comprises
- the composite powder exhibits excellent overall properties over many aspects of safety and usability, and the preferred composite powder of the present invention does not use expensive raw materials such as silver-zinc-substituted zeolite.
- the content of the composite powder according to the present invention contained in the cosmetic of the present invention is not particularly limited as long as the effects of the present invention can be obtained, and can be appropriately adjusted and used. 0.5 to 60% by mass. If the amount is less than 0.5% by mass, the effects of the present invention may not be exhibited. If the amount is more than 60% by mass, the formulation may be unfavorable.
- components used in ordinary cosmetics for example, humectants, antioxidants, oily components, ultraviolet absorbers, emulsifiers, as long as the effects of the present invention are not impaired, Surfactants, thickeners, alcohols, powder components, coloring materials, aqueous components, water, various skin nutrients, and the like can be appropriately compounded as necessary.
- sequestering agents such as sodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, gnoreconic acid, malic acid, caffeine, tannin, verapamil, tranexamic acid and its derivatives, licorice, Various herbal extracts such as karin and ithaxo, etc., drugs such as tocopherol acetate, glycyrrhetinic acid, glycyrrhizic acid and derivatives or salts thereof, vitamins, magnesium ascorbate, darcoside ascorbate, arbutin, kojic acid and other whitening agents , Arginine, lysine and other amino acids and their derivatives, and sugars such as fructose, mannose, erythritol, trehalose, xylitol and the like can also be appropriately compounded.
- drugs such as tocopherol acetate, glycyrrhetinic acid,
- the cosmetics of the present invention include, for example, ointments, creams, emulsions, lotions, nonk, foundations, lipsticks, eye shadows, white powders, lipsticks, bath agents, oil blotting paper, paper paste, body powders, baby powders, powders It can be applied in any form as long as it is used for conventional cosmetics such as a spray, and the dosage form is not particularly limited.
- the composite powder according to the present invention also has an excellent effect on application to skin where conventional cosmetics such as sensitive skin have been difficult to use.
- sensitive skin is described as follows. "Normal skin, which usually reacts specifically to substances that are nothing to many, such as external medicines, cosmetics, plants, ultraviolet rays, and metals, which causes skin problems. (Pollen, fragrance, etc.) and irritating substances (alcohol, etc.), and the skin's natural resistance due to lack of sleep, overwork, physiology, seasonal changes, mental stress, etc. Or skin that is susceptible to temporary skin problems with irritants when the physiological function of the skin is weakened.
- Factors that make skin conditions sensitive include decreased skin paria function, decreased skin irritation threshold, dry skin, contact dermatitis inflammation, physicochemical irritation, stress, physical condition, and seasonal changes. , Ultraviolet light, physiology and the like. In addition, there are cases where the skin becomes sensitive due to wrong skin care, or is simply classified as sensitive based on the person's belief. Conceivable.
- a sensitive skin subject is defined as a person who has an abnormal sensation in any of the following processes (1) to (4).
- Impregnate 2 ⁇ 2 cm nonwoven fabric with 100 ⁇ L of 0.2% aqueous solution of methylparaben, and let stand for 10 minutes.
- the abnormal sensation means a relatively painful sensation in the skin area, for example, tingling, itching, itching, heat, discomfort, stabbing pain and the like.
- the composite powder of the present invention can be used for paper supplies and office supplies such as tissue paper, paper towels, napkins, banknotes, tickets, tickets, books, posters, newspapers, magazines, notebooks, notepads; underwear, underwear, shirts, Hats, shoes and other linings, socks, sandals, and other clothing; nursing such as disposable diapers for infants and the elderly; nursing care products; sanitary products, contraceptives, kitchen sponges, scourers, toilet seats, toilet seat covers, rags, toothbrushes.
- the reaction was carried out while adjusting the dropping amounts of the two aqueous solutions while maintaining the pH at 8 during the reaction while stirring at normal pressure and normal temperature.
- the dropping time was about 30 minutes.
- the obtained precipitate was washed and filtered three times, dried in an oven at 105 ° C for 12 hours, pulverized by a personal mill, and calcined at 300 for 1 hour. This powder was pulverized and passed through a 60-mesh sieve to obtain an intended product.
- Test Example 1 The same operation as in Test Example 1 was carried out except that in the Test Example 1, talc was used instead of My force (Eight Pearl 300 S TM : manufactured by Kakuhachi Fish Scale Co., Ltd., ⁇ potential: 18.9 mV). I got something.
- talc was used instead of My force (Eight Pearl 300 S TM : manufactured by Kakuhachi Fish Scale Co., Ltd., ⁇ potential: 18.9 mV). I got something.
- the firing step was omitted in Test Example 1 to obtain a basic zinc carbonate composite powder.
- Test Example 1 The same operation as in Test Example 1 was performed except that alumina (Max Light A-100 TM: Showa Denko KK, ⁇ potential: +17.3 mV) was used in place of talc in Test Example 1. Obtained.
- alumina Max Light A-100 TM: Showa Denko KK, ⁇ potential: +17.3 mV
- Test Example 1 the same operation was performed without adding talc, and the combined use of zinc oxide and sodium carbonate was repeated. Get the compound. 10 g of this composite and 50 g of talc were uniformly stirred and mixed with a small mixer to obtain a desired mixture.
- FIG. 5 is an explanatory diagram of a method for evaluating antibacterial and antifungal performance.
- Potato dextrose agar was used for fungal testing, and normal bouillon agar was used for bacterial testing.
- a culture medium 24 is formed in a petri dish 22.
- fungi [Penicillium sp., Black mold (Aspergillus niger), Candida albicans ATCC10231), bacteria [Pseudomonas aeruginosa ATCC15442), Escherichia coli (Escherichia coli ATCC8739), Staphylococcus aureus (Staphylococcus aureus FDA209P), Acne bacteria (P.
- Tris-HC1 buffer pH 7.5 was added to 20 ⁇ L of each of the powder suspensions of Test Examples 1 to 11 to make a total volume of 180, and 30 OU / mL of activated perokinase (UK) 2 0 ⁇ L was added and left at room temperature. Thirty minutes later, S 2444 (CHR0M0GENIX), a UK-specific synthetic substrate, was added at 20 / z L, and the mixture was allowed to stand in a 37 ° C constant temperature bath for 30 minutes.
- S 2444 CHR0M0GENIX
- Test Example 7 using only zinc oxide was inferior in both antibacterial and antifungal performance as compared with Test Examples 1 to 4 that were the composite powder of the present invention.
- zinc oxide was originally known as an inorganic antibacterial substance, but this alone did not provide sufficient antibacterial and antifungal properties. It was found to improve.
- Test Example 8 which is a commercially available inorganic antibacterial agent, the antibacterial and antimicrobial performance was inferior to those of Test Examples 1 to 4 which were the composite powder of the present invention.
- Test Example 5 using alumina with a positive ⁇ potential had lower antibacterial and antifungal performance against Escherichia coli than Test Examples 1 to 4 using talc, my force, and silica with a negative ⁇ potential.
- Test Example 6 in which talc was simply mixed with the complex of zinc acid acid and alkali metal salt the antibacterial and antibacterial properties against Escherichia coli were low.
- Test Example 5 using alumina with a positive ⁇ potential for the adsorption site showed a lower ⁇ ⁇ inhibition rate than Test Examples 1-4 using talc, my force, and silica with a negative ⁇ potential for the adsorption site. was low. This is thought to be because the ⁇ potential is positive and ⁇ cannot be adsorbed.
- Test Example 6 in which talc equivalent to the adsorption site was simply mixed with the action site, the PA inhibition rate was low, and as shown in Test Examples 1 to 4, the inhibition rate was reduced by combining the adsorption site and the action site. It was confirmed that a significant improvement was observed. This is presumably because the mere mixing of the adsorption site and the action site causes the particles to move, so that the adsorption site cannot stably have a negative potential.
- the antibacterial and antifungal effect of the composite powder of the present invention was improved by combining zinc oxide with an alkali metal salt. It is also effective against acne bacteria and has the effect of suppressing acne. Furthermore, it was confirmed that by combining the adsorption site with a negative ⁇ potential and the action site, an excellent ⁇ ⁇ inhibitory effect was exhibited.
- a specific test method for the antibacterial and antifungal properties, irritation, and lightness of spread of the cosmetic containing the composite powder of the present invention and the criteria for the determination will be described below.
- Test method JISZ 2 9 1 1
- Each sample was molded into a medium dish based on the mold resistance test, sprayed with a mold, covered, left in a 25 ° C constant temperature bath under humid conditions, and visually inspected for mold. Observe for growth.
- Test method applied to 20 panelists and asked if they felt irritation 0 minutes later c
- Test method Sensory evaluation was performed by 20 specialized panels.
- Formulation Example 4 using a commercially available zinc oxide and Formulation Example 5 using a commercially available antibacterial and fungicide showed no irritation, but showed antibacterial and antifungal performance and lightness. It was inferior in point.
- Formulation Example 6 using ethylparaben the antibacterial and antifungal properties and the lightness of the growth were good, but the irritation was inferior.
- Formulation Example 13 using the composite powder according to the present invention sufficient antibacterial and antimicrobial performance was exhibited without blending ethiparaben. The growth was also light and non-irritating.
- the cosmetic of Formulation Example 13 using the composite powder according to the present invention also exhibited antibacterial and antifungal properties against acne bacteria, and was found to be effective on acne skin.
- the powder obtained in Test Example 14 was analyzed by X-ray fluorescence, X-ray diffraction, and infrared absorption spectroscopy.
- the active site was zinc oxide as the main component, and 21.5% by mass of sodium carbonate. was found to exist. Examination of raw materials for synthesis of zinc oxide and / or basic zinc carbonate
- the reaction was carried out while controlling the pH of the two aqueous solutions dropwise while maintaining the pH at a constant value while stirring at normal pressure and normal temperature.
- the dropping time was about 30 minutes.
- the obtained precipitate was washed and filtered three times, dried in an oven at 120 ° C for 12 hours, pulverized by a personal mill, and calcined at 450 for 1 hour. This powder was ground and passed through a 60-mesh sieve to obtain the desired product.
- Test Example 12 The same operation as in Test Example 12 was performed, except that 59.3 g of zinc sulfate was used instead of 50.1 g of zinc chloride in Test Example 12, to obtain an intended product.
- Test Example 16 The same operation as in Test Example 12 was carried out except for removing acetic acid in Test Example 12, to obtain the desired product.
- Test Example 16 The same operation as in Test Example 12 was carried out except for removing acetic acid in Test Example 12, to obtain the desired product.
- Test example 1 7 Except for the acetic acid of Test Example 12, the same operation as in Test Example 12 was carried out, except that 24.5 g of sodium hydroxide was used instead of 130 g of anhydrous sodium carbonate, to obtain an intended product.
- Test example 1 7 Except for the acetic acid of Test Example 12, the same operation as in Test Example 12 was carried out, except that 24.5 g of sodium hydroxide was used instead of 130 g of anhydrous sodium carbonate, to obtain an intended product. Test example 1 7
- Test Example 12 Except for the acetic acid of Test Example 12, the same operation as in Test Example 12 was carried out except that 90 g of anhydrous sodium carbonate was used instead of 130 g of anhydrous sodium carbonate, to obtain an intended product.
- the powders obtained in Test Examples 12 to 16 were tested for PA inhibitory activity and antibacterial and antifungal performance according to the above-mentioned method 'standards. Table 4 shows the results.
- the PA inhibition rate was excellent in all the examples, but the powders of Test Examples 12 to 14 were lower than the powders of Test Examples 15 and 16 in each sample. It was found to have excellent antibacterial and antifungal properties against bacteria. Therefore, it is preferable to use zinc acetate, zinc sulfate, or zinc chloride as a raw material for synthesizing zinc oxide and zinc oxide or basic zinc carbonate. It is preferred to add twice as many moles of acetic acid. Furthermore, the antibacterial and antifungal properties of the cosmetics containing the powders obtained in Test Examples 12, 3, 14, 16 and 17 were tested.
- Test example 1 7 5 Test example 1 6 5 My power 2 0 2 0 2 0 20 20
- the alkali metal salt may flow out by washing the powder, and the effect is reduced by half.
- Content of zinc oxide and / or basic zinc carbonate may flow out by washing the powder, and the effect is reduced by half.
- talc (EN- 24 R TM: Asada Milling Co., zeta potential: over 1 7. OMV) dispersing 1 0 0 g.
- talc Asada Milling Co., zeta potential: over 1 7. OMV
- two microtube pumps were connected, and a controller and a stirrer were set.
- Two micro tubes A pump was connected to a solution in which zinc chloride and acetic acid were dissolved in ion-exchanged water and a solution in which anhydrous sodium carbonate was dissolved in ion-exchanged water, and fixed so that the solution could be dropped into the reaction vessel.
- Each solution was varied as shown in Table 6.
- the reaction was carried out while adjusting the dropping amounts of the two aqueous solutions while maintaining the pH at a constant value during the reaction while stirring at normal pressure and normal temperature.
- the dropping time was about 30 minutes.
- the obtained precipitate was repeatedly washed and filtered three times, dried in an oven at 105 ° C for 12 hours, pulverized by a personal mill, and fired at 300 ° C for 1 hour.
- This powder was pulverized and passed through a 100-mesh sieve to obtain a target substance having a different content of zinc oxide. These are referred to as Test Examples 18_2 to 18-11 according to the content of zinc oxide as described in Table 6.
- Test example 18-2 1 8 1.67 1.48 13.5 4.42
- Test example 18-5 20 160 33.4 29.6 270 88.4
- Test example 18-7 40 320 66.8 59.2 540 176.8
- Test example 18-9 60 480 100.2 88.8 810 265.2
- Test example 18-10 75 600 125.25 111 1012.5 331.5
- Test Example 18 The PA inhibitory effect, antibacterial and antibacterial performance, and lightness of the powder of No. 18-11 were tested according to the above methods and criteria. Table 7 shows the results. [Table 7]
- Test example 18 2 5 — — — — — — — One — —
- Test example 18 3—5 ——— one —————
- Test example 18 7 —————— 5
- the reaction was carried out while adjusting the dropping amounts of the two aqueous solutions while maintaining the pH at 8 during the reaction while stirring at normal pressure and normal temperature.
- the dropping time was about 30 minutes.
- the obtained precipitate was washed and filtered three times, dried in an oven at 105 ° C for 12 hours, pulverized by a personal mill, and calcined at 300 ° C for 1 hour. This powder was ground and passed through a 60-mesh sieve to obtain a preliminary powder (composite powder of talc and zinc oxide).
- the preliminary powder was added to an aqueous solution in which sodium carbonate was dissolved in 2 OmL of ion-exchanged water, mixed well with a homomixer, and dried at 110 ° C. for 14 hours using an oven to obtain an intended product. .
- the mixing amount of sodium carbonate and the preliminary powder was changed as shown in Table 9, and composite powders with different contents of the alkali metal salt were obtained.
- Test example 19-1 10 0 0
- Test example 19-4 9.9 0.1 1.00
- Test Example 19-6 9.5 0.5 5.00
- Test Example 19-11 0 10 100.00 Test Example 19 The powders of 9-1-1 to 191-11 were tested for PA inhibitory activity and antibacterial and antifungal performance in accordance with the above methods and criteria. Table 10 shows the results. [Table 10]
- the antibacterial protection performance was hardly observed in Test Example 19-11 using only the preliminary powder, and was improved as the content of sodium carbonate was 0.5 mass% or more and the content increased.
- the content of sodium carbonate is 75% by mass or more, there is a concern that the high hygroscopicity and dissolution of sodium carbonate may degrade the performance of the composition, and the strong alkalinity of the antibacterial agent itself may affect the human body. Is done.
- Test Example 19-11 in which the content of sodium carbonate was 100% by mass, the effect on blue and black velvet was reduced.
- the content of the alkali metal salt was preferably 0.5 to 50% by mass of the entire composite powder.
- Test example 19 10 5 —
- Antibacterial protection performance ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ Irritant ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ Easy to spread ⁇ ⁇ ⁇ ⁇ — ⁇ ⁇ ⁇ ⁇ ⁇ _ ⁇ ⁇ ⁇
- Test Example 19-10 which was 100% by mass of sodium carbonate.
- the content of sodium carbonate was good at 1 to 75% by mass. If the content of sodium carbonate is 75% by mass or more, the performance of the composition is deteriorated due to the high hygroscopicity and dissolution of sodium carbonate, or the antibacterial agent itself may become strongly alkaline. To be reminded.
- the content of the alkali metal salt is preferably 0.5 to 50% by mass of the whole composite powder in the powder-containing cosmetic.
- Figure 6 shows the relationship between the antifungal performance against blue mold and the pH of the aqueous dispersion when the composite powder is dispersed in water to form a 10% by mass slurry.
- the antifungal performance is indicated by the width of the growth inhibition zone according to the method described above.
- the powder having a high force-proofing property has an aqueous dispersion having a pH of 9 to 14, especially 9.5 to 12. Therefore, the pH of the 10% by mass aqueous dispersion is preferably from 9 to 14, and most preferably from 9.5 to 12.
- Test example 20-1 6 350 1 1 5.5
- Test Example 20- 725 EEEEEEE From Table 13, the PA inhibition rate was higher when the pH at the time of synthesis was 711, and the antibacterial and antifungal performance was superior when the pH at the time of synthesis was 610. From the above results, it is preferable that the pH during the synthesis is 710. This is because, when the pH at the time of synthesis is controlled at 710, the aqueous dispersion of the synthesized powder tends to show pH 9.14, and as described above, it has excellent PA inhibitory activity and antibacterial and antifungal performance. It is considered that this is the case.
- the pH of the 10% by mass aqueous dispersion of the composite powder is preferably 914.
- Each of the cosmetics of Formulation Example 14 had excellent antibacterial and antifungal properties and was non-irritating.
- Example 15 Sticking to Leather, Wood, etc.
- the composite powder of the present invention is imprinted with a binder made of a synthetic resin, heat-treated, and the composite powder is fixed by the resin, thereby providing an antibacterial and antifungal effect and suppressing skin roughness. ⁇ Improvement effect is exhibited.
- Example 16 Coating on glass, metal, etc.
- Example 17 Filling into paper, fiber, etc.
- Paper is an extremely coarse porous sheet originally made of vegetable fibers. When the composite powder of the present invention is filled here, it is held inside and exhibits an antibacterial and antifungal effect, and a roughening suppression / improvement effect.
- Example 1 8 Formulation in laundry detergent, fabric softener, etc.
- Example 1 9 Formulation into a single product
- Example 20 Formulation into paste, varnish, lacquer, paint, etc.
- the composite powder of the present invention By mixing the composite powder of the present invention with materials such as paste, varnish, lacquer, and paint, not only the material itself, but also the material to which it is applied and adhered, has an antibacterial and antifungal effect and suppresses rough skin The improvement effect is exhibited.
- excellent antibacterial and antibacterial properties can be obtained by containing zinc oxyacid and / or basic zinc carbonate and an alkali metal salt. be able to.
- adsorption site with an active site containing zinc oxide and / or basic zinc carbonate and an alkaline metal salt, a complex having a plasminogen activator-inhibiting effect in addition to an antibacterial and antifungal effect. Powder can be obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003579768A JP4376634B2 (ja) | 2002-03-29 | 2003-03-28 | 複合粉体及びそれを含む化粧料 |
EP03715576A EP1498100A4 (en) | 2002-03-29 | 2003-03-28 | COMPOSITE POWDER AND THIS INCLUDING COSMETICS |
US10/509,660 US7381415B2 (en) | 2002-03-29 | 2003-03-28 | Composite powder and cosmetic containing the same |
KR1020047013448A KR100984906B1 (ko) | 2002-03-29 | 2003-03-28 | 복합 분체와 이를 포함하는 화장료 |
HK06100608A HK1080723A1 (en) | 2002-03-29 | 2006-01-13 | Composite powder and cosmetic containing the same |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-96254 | 2002-03-29 | ||
JP2002-96255 | 2002-03-29 | ||
JP2002096254 | 2002-03-29 | ||
JP2002096255 | 2002-03-29 | ||
JP2002-355789 | 2002-06-12 | ||
JP2002-355790 | 2002-06-12 | ||
JP2002355789 | 2002-12-06 | ||
JP2002355790 | 2002-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003082229A1 true WO2003082229A1 (en) | 2003-10-09 |
Family
ID=28679001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/003946 WO2003082229A1 (en) | 2002-03-29 | 2003-03-28 | Composite powder and cosmetic containing the same |
Country Status (8)
Country | Link |
---|---|
US (1) | US7381415B2 (ja) |
EP (1) | EP1498100A4 (ja) |
JP (1) | JP4376634B2 (ja) |
KR (1) | KR100984906B1 (ja) |
CN (1) | CN100340224C (ja) |
HK (1) | HK1080723A1 (ja) |
TW (1) | TWI306765B (ja) |
WO (1) | WO2003082229A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004204403A (ja) * | 2002-12-26 | 2004-07-22 | Shiseido Co Ltd | 複合粉体含有材料 |
WO2004082649A1 (en) * | 2003-03-18 | 2004-09-30 | The Procter & Gamble Company | Augmentation of pyrithione activity or a polyvalent metal salt of pyrithione activity by zinc-containing layered material |
CN103263894A (zh) * | 2013-05-08 | 2013-08-28 | 南京南大药业有限责任公司 | 一种尿激酶快速吸附袋 |
JP2015502828A (ja) * | 2011-12-23 | 2015-01-29 | ロレアル | メイクアップ方法 |
US9381148B2 (en) | 2003-03-18 | 2016-07-05 | The Procter & Gamble Company | Composition comprising particulate zinc material with a high relative zinc lability |
WO2016199907A1 (ja) * | 2015-06-12 | 2016-12-15 | Jfeミネラル株式会社 | 皮膚創傷または皮膚荒れ治療剤 |
JP2018502226A (ja) * | 2014-10-28 | 2018-01-25 | レンツィング アクチェンゲゼルシャフト | 酸化亜鉛含有のセルロース繊維を含む液体含浸された不織布 |
WO2018105739A1 (ja) * | 2016-12-09 | 2018-06-14 | Jfeミネラル株式会社 | 亜鉛イオン徐放性に優れる無機組成物およびその製造方法 |
JP2018150266A (ja) * | 2017-03-13 | 2018-09-27 | 日本メナード化粧品株式会社 | ニキビ予防及び/又は改善用皮膚外用剤 |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2417356T3 (es) * | 2001-06-29 | 2013-08-07 | Shiseido Company, Ltd. | Polvos compuestos y preparaciones para aplicación externa que contiene dichos polvos |
WO2003088957A1 (en) * | 2002-04-22 | 2003-10-30 | The Procter & Gamble Company | Personal care compositions comprising a zinc containing material in an aqueous surfactant composition |
US7578997B2 (en) | 2002-04-30 | 2009-08-25 | Kimberly-Clark Worldwide, Inc. | Metal ion modified high surface area materials for odor removal and control |
US7976855B2 (en) * | 2002-04-30 | 2011-07-12 | Kimberly-Clark Worldwide, Inc. | Metal ion modified high surface area materials for odor removal and control |
US8367048B2 (en) | 2002-06-04 | 2013-02-05 | The Procter & Gamble Company | Shampoo containing a gel network |
US8470305B2 (en) | 2002-06-04 | 2013-06-25 | The Procter & Gamble Company | Shampoo containing a gel network |
US8349302B2 (en) * | 2002-06-04 | 2013-01-08 | The Procter & Gamble Company | Shampoo containing a gel network and a non-guar galactomannan polymer derivative |
US9381382B2 (en) * | 2002-06-04 | 2016-07-05 | The Procter & Gamble Company | Composition comprising a particulate zinc material, a pyrithione or a polyvalent metal salt of a pyrithione and a gel network |
US8361450B2 (en) | 2002-06-04 | 2013-01-29 | The Procter & Gamble Company | Shampoo containing a gel network and a non-guar galactomannan polymer derivative |
US8361448B2 (en) * | 2002-06-04 | 2013-01-29 | The Procter & Gamble Company | Shampoo containing a gel network |
US8349301B2 (en) | 2002-06-04 | 2013-01-08 | The Procter & Gamble Company | Shampoo containing a gel network |
JP2004217621A (ja) * | 2002-12-27 | 2004-08-05 | Shiseido Co Ltd | 油性皮膚外用剤 |
US7141518B2 (en) * | 2003-10-16 | 2006-11-28 | Kimberly-Clark Worldwide, Inc. | Durable charged particle coatings and materials |
US7678367B2 (en) | 2003-10-16 | 2010-03-16 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using metal-modified particles |
US7879350B2 (en) | 2003-10-16 | 2011-02-01 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using colloidal nanoparticles |
US20060171971A1 (en) * | 2005-02-01 | 2006-08-03 | The Procter & Gamble Company | Composition for wet wipes containing a non-irritating skin health benefit ingredient and the process for making |
US20070094893A1 (en) * | 2005-09-02 | 2007-05-03 | Veronica Flores | Disposable flip-flop with exfoliating and moisturizing functions |
KR100871423B1 (ko) * | 2006-10-30 | 2008-12-03 | 김용국 | 기능성 화장품 및 그의 제조방법 |
US9050355B2 (en) * | 2007-12-18 | 2015-06-09 | Dr. Varatus Vongsurakrai | Method for producing cosmetic and/or dermatological powder |
ES2319158B1 (es) * | 2008-12-23 | 2010-01-26 | Grifols, S.A | Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa. |
US9314027B2 (en) * | 2009-04-02 | 2016-04-19 | University Of Florida Research Foundation, Inc. | Functionalized fullerenes as antifungal agents |
EP2536389A2 (en) * | 2010-02-16 | 2012-12-26 | The Procter & Gamble Company | Method for providing maximum malodor and irritation control |
EP2536386A1 (en) | 2010-02-16 | 2012-12-26 | The Procter & Gamble Company | A porous, dissolvable solid substrate and surface resident coating comprising a zync pyrithione |
ITMI20100286A1 (it) * | 2010-02-23 | 2011-08-24 | Art Cosmetics Srl | Composizione cosmetica per il trucco (make-up) e processo per la sua preparazione |
CN101953765B (zh) * | 2010-09-10 | 2011-09-07 | 浙江省农业科学院 | 一种蚕丝爽身粉及其制备工艺 |
FR2964871B1 (fr) * | 2010-09-17 | 2012-10-19 | Oreal | Composition cosmetique solide de maquillage |
KR101356744B1 (ko) * | 2010-10-28 | 2014-02-05 | 주식회사 케미랜드 | 피부 친화적 점토 광물에 실리콘 오일을 코팅한 복합 분체 및 그의 제조방법 |
CN104202987B (zh) | 2011-08-15 | 2017-09-01 | 宝洁公司 | 个人护理方法 |
ES2642364T3 (es) | 2011-10-07 | 2017-11-16 | The Procter & Gamble Company | Composición de champú que contiene una red de gel |
KR101356741B1 (ko) * | 2011-10-31 | 2014-02-05 | 주식회사 케미랜드 | 자외선 차단 기능성 화장료용 일라이트 복합 분체 및 그의 제조방법 |
WO2013166718A1 (en) | 2012-05-11 | 2013-11-14 | The Procter & Gamble Company | Personal cleansing compositions comprising zinc pyrithione |
CA2901658A1 (en) | 2013-03-14 | 2014-09-18 | The Procter & Gamble Company | Bar soap compositions containing zinc pyrithione and a zinc-pyridine oxide complex |
WO2014169464A1 (en) | 2013-04-18 | 2014-10-23 | The Procter & Gamble Company | Personal care compositions containing zinc pyrithione and zinc-phosphonate complex |
US10201481B2 (en) | 2014-03-07 | 2019-02-12 | The Procter & Gamble Company | Personal care compositions and methods of making same |
EP3291790A1 (en) | 2015-05-06 | 2018-03-14 | The Procter and Gamble Company | Methods of cosmetically treating skin conditions with a cosmetic personal cleansing composition |
DE102016100083B4 (de) * | 2016-01-04 | 2019-02-14 | Refractory Intellectual Property Gmbh & Co. Kg | Feuerfeste Formkörper und Massen sowie Bindemittel und Verfahren zu deren Herstellung |
TWI597326B (zh) * | 2016-03-22 | 2017-09-01 | 台鉅企業股份有限公司 | 複合粉體及其製造方法暨含彼之化妝品組成物 |
US10945935B2 (en) | 2016-06-27 | 2021-03-16 | The Procter And Gamble Company | Shampoo composition containing a gel network |
KR101819467B1 (ko) * | 2016-08-26 | 2018-01-18 | 코스맥스 주식회사 | 압전 화장료 조성물 |
JP6871947B2 (ja) * | 2016-12-09 | 2021-05-19 | Jfeミネラル株式会社 | 亜鉛イオン徐放性に優れる塩化水酸化亜鉛およびその製造方法 |
CN112261931B (zh) | 2018-06-05 | 2023-12-08 | 宝洁公司 | 透明清洁组合物 |
EP3894015A1 (en) | 2018-12-14 | 2021-10-20 | The Procter & Gamble Company | Shampoo composition comprising sheet-like microcapsules |
US11896689B2 (en) | 2019-06-28 | 2024-02-13 | The Procter & Gamble Company | Method of making a clear personal care comprising microcapsules |
CN110817934A (zh) * | 2019-09-30 | 2020-02-21 | 成都理工大学 | 一种叶蜡石负载纳米ZnO复合抗紫外剂及其制备技术 |
CN110817932A (zh) * | 2019-09-30 | 2020-02-21 | 成都理工大学 | 一种伊利石负载纳米ZnO复合抗紫外剂及其制备技术 |
CN111297710B (zh) * | 2019-11-06 | 2023-03-24 | 成都理工大学 | 一种白云母负载纳米ZnO复合抗紫外剂及其制备方法 |
CN111557858B (zh) * | 2019-11-06 | 2023-03-31 | 成都理工大学 | 一种伊利石负载纳米ZnO复合抗紫外剂及其制备方法 |
EP4103335A1 (en) | 2020-02-14 | 2022-12-21 | The Procter & Gamble Company | Bottle adapted for storing a liquid composition with an aesthetic design suspended therein |
US11633072B2 (en) | 2021-02-12 | 2023-04-25 | The Procter & Gamble Company | Multi-phase shampoo composition with an aesthetic design |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2544218A1 (de) | 1975-10-03 | 1977-04-21 | Basf Ag | Verfahren zur herstellung von zinkoxidhaltigen fuellstoffen |
FR2729132A1 (fr) * | 1994-12-30 | 1996-07-12 | Miki America Inc | Composite particulaire, procede pour sa production et composition cosmetique le contenant |
EP1112744A1 (en) | 1999-12-24 | 2001-07-04 | Shiseido Company Limited | Zinc oxide as plasminogen activator inhibitor for external use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5482720A (en) * | 1994-10-11 | 1996-01-09 | Church & Dwight Co., Inc. | Encapsulated co-micronized bicarbonate salt compositions |
KR100467025B1 (ko) * | 1997-01-29 | 2007-05-04 | 주식회사 엘지생활건강 | 항균성파우더를함유하는세안제조성물 |
-
2003
- 2003-03-28 CN CNB038074087A patent/CN100340224C/zh not_active Expired - Fee Related
- 2003-03-28 EP EP03715576A patent/EP1498100A4/en not_active Withdrawn
- 2003-03-28 KR KR1020047013448A patent/KR100984906B1/ko not_active IP Right Cessation
- 2003-03-28 WO PCT/JP2003/003946 patent/WO2003082229A1/ja active Application Filing
- 2003-03-28 TW TW092107071A patent/TWI306765B/zh not_active IP Right Cessation
- 2003-03-28 JP JP2003579768A patent/JP4376634B2/ja not_active Expired - Fee Related
- 2003-03-28 US US10/509,660 patent/US7381415B2/en not_active Expired - Fee Related
-
2006
- 2006-01-13 HK HK06100608A patent/HK1080723A1/xx not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2544218A1 (de) | 1975-10-03 | 1977-04-21 | Basf Ag | Verfahren zur herstellung von zinkoxidhaltigen fuellstoffen |
FR2729132A1 (fr) * | 1994-12-30 | 1996-07-12 | Miki America Inc | Composite particulaire, procede pour sa production et composition cosmetique le contenant |
US5968531A (en) | 1994-12-30 | 1999-10-19 | Miki America, Inc. | Particulate composite, method of producing thereof, and cosmetic containing particulate composite |
EP1112744A1 (en) | 1999-12-24 | 2001-07-04 | Shiseido Company Limited | Zinc oxide as plasminogen activator inhibitor for external use |
Non-Patent Citations (1)
Title |
---|
See also references of EP1498100A4 |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004204403A (ja) * | 2002-12-26 | 2004-07-22 | Shiseido Co Ltd | 複合粉体含有材料 |
WO2004082649A1 (en) * | 2003-03-18 | 2004-09-30 | The Procter & Gamble Company | Augmentation of pyrithione activity or a polyvalent metal salt of pyrithione activity by zinc-containing layered material |
US9381148B2 (en) | 2003-03-18 | 2016-07-05 | The Procter & Gamble Company | Composition comprising particulate zinc material with a high relative zinc lability |
US11246820B2 (en) | 2011-12-23 | 2022-02-15 | L'oreal | Makeup process |
JP2015502828A (ja) * | 2011-12-23 | 2015-01-29 | ロレアル | メイクアップ方法 |
CN103263894A (zh) * | 2013-05-08 | 2013-08-28 | 南京南大药业有限责任公司 | 一种尿激酶快速吸附袋 |
CN103263894B (zh) * | 2013-05-08 | 2015-06-24 | 南京南大药业有限责任公司 | 一种尿激酶快速吸附袋 |
JP2018502226A (ja) * | 2014-10-28 | 2018-01-25 | レンツィング アクチェンゲゼルシャフト | 酸化亜鉛含有のセルロース繊維を含む液体含浸された不織布 |
WO2016199907A1 (ja) * | 2015-06-12 | 2016-12-15 | Jfeミネラル株式会社 | 皮膚創傷または皮膚荒れ治療剤 |
JPWO2016199907A1 (ja) * | 2015-06-12 | 2018-03-29 | Jfeミネラル株式会社 | 皮膚創傷または皮膚荒れ治療剤 |
CN107847522A (zh) * | 2015-06-12 | 2018-03-27 | 杰富意矿物股份有限公司 | 皮肤创伤或皮肤粗糙治疗剂 |
WO2018105739A1 (ja) * | 2016-12-09 | 2018-06-14 | Jfeミネラル株式会社 | 亜鉛イオン徐放性に優れる無機組成物およびその製造方法 |
JPWO2018105739A1 (ja) * | 2016-12-09 | 2019-10-24 | Jfeミネラル株式会社 | 亜鉛イオン徐放性に優れる無機組成物およびその製造方法 |
US10987380B2 (en) | 2016-12-09 | 2021-04-27 | Jfe Mineral Company, Ltd. | Hydrozincite containing zinc carbonate hydroxide hydrate and method of making |
JP2018150266A (ja) * | 2017-03-13 | 2018-09-27 | 日本メナード化粧品株式会社 | ニキビ予防及び/又は改善用皮膚外用剤 |
Also Published As
Publication number | Publication date |
---|---|
CN100340224C (zh) | 2007-10-03 |
TW200306860A (en) | 2003-12-01 |
US20050181067A1 (en) | 2005-08-18 |
US7381415B2 (en) | 2008-06-03 |
CN1642514A (zh) | 2005-07-20 |
KR20040102360A (ko) | 2004-12-04 |
HK1080723A1 (en) | 2006-05-04 |
JP4376634B2 (ja) | 2009-12-02 |
EP1498100A4 (en) | 2008-04-02 |
JPWO2003082229A1 (ja) | 2005-07-28 |
KR100984906B1 (ko) | 2010-10-01 |
EP1498100A1 (en) | 2005-01-19 |
TWI306765B (en) | 2009-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4376634B2 (ja) | 複合粉体及びそれを含む化粧料 | |
EP2346473B1 (en) | Powder makeup compositions and methods | |
JP2006523735A (ja) | 抗菌顔料 | |
WO2005087182A1 (ja) | 機能性粉体 | |
KR101089438B1 (ko) | 복합분체 및 이를 배합시킨 피부외용제 | |
KR20070057380A (ko) | 분체 상의 화장료 조성물 | |
US6649179B2 (en) | Method for improving morbid dermatitis by inhibiting activity of a plasminogen activator in the skin | |
US20040253284A1 (en) | Sebum-adsorbent powder and use thereof | |
EP1576947B1 (en) | Oily skin preparation for external use containing a complex powder | |
JP2002212032A (ja) | メーキャップ化粧料 | |
JP2000159632A (ja) | 皮膚抗菌性組成物 | |
JP4326689B2 (ja) | プラスミノーゲンアクチベーター阻害剤およびそれを配合した皮膚外用剤 | |
JP3771199B2 (ja) | 化粧料 | |
JP4728517B2 (ja) | 皮膚外用剤 | |
JP6034618B2 (ja) | 化粧料 | |
JP2003012491A (ja) | 粉体皮膚外用剤 | |
JP2004204403A (ja) | 複合粉体含有材料 | |
CN112972336B (zh) | 一种肌肤美白保湿乳液及其制备方法 | |
KR100876914B1 (ko) | 은 나노입자 및 유기 게르마늄을 함유한 기능성 비누 조성물 | |
JP2003012558A (ja) | 固化性皮膚外用剤 | |
KR20050090300A (ko) | 황토 및 (또는) 은 분말을 함유하는 피부미용 화장팩 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CN JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020047013448 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003579768 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038074087 Country of ref document: CN Ref document number: 10509660 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003715576 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047013448 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003715576 Country of ref document: EP |